The role of immunotherapy in microsatellites stable metastatic colorectal cancer: state of the art and future perspectives

The role of immunotherapy in microsatellites stable metastatic colorectal cancer: state of the art and future perspectives

Colorectal cancer (CRC) is the third leading cause of cancer-related deaths worldwide, despite several advances has been achieved in last decades. Few prognostic and predictive biomarkers guide therapeutic choice in metastatic CRC (mCRC), among which DNA mismatch repair deficiency and/or microsatell...

Full description

Bibliographic Details
Main Authors:	Annalice Gandini, Silvia Puglisi, Chiara Pirrone, Valentino Martelli, Fabio Catalano, Simone Nardin, Andreas Seeber, Alberto Puccini, Stefania Sciallero
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-05-01
Series:	Frontiers in Oncology
Subjects:	microsatellite stable MSS colorectal cancer immunotherapy checkpoint inhibitors combination strategy
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1161048/full

Similar Items

Immunotherapy combined with local therapy in the late-line treatment of repair-proficient (pMMR)/microsatellite stable (MSS) metastatic colorectal cancer
by: Yuwei Ding, et al.
Published: (2023-11-01)

Editorial: New therapeutic approaches in microsatellite stable colorectal cancer patients
by: Michela Bartolini, et al.
Published: (2023-07-01)

Advances in immune checkpoint inhibitor combination strategies for microsatellite stable colorectal cancer
by: Javier Ros, et al.
Published: (2023-02-01)

Efficacy, safety and predictors of combined fruquintinib with programmed death-1 inhibitors for advanced microsatellite-stable colorectal cancer: A retrospective study
by: Weijie Zhang, et al.
Published: (2022-08-01)

Research Progress on Combined Immunotherapy for Microsatellite Stable Colorectal Cancer
by: YIN Zhucheng, et al.
Published: (2022-09-01)

High and low dose radiotherapy combined with ICIs for MSS colorectal cancer patients with liver metastases: a phase I study (HaRyPOT)
by: Yuxuan Ding, et al.
Published: (2025-02-01)

Complete response of metastatic microsatellite-stable BRAF V600E colorectal cancer to first-line oxaliplatin-based chemotherapy and immune checkpoint blockade
by: Anne Hansen Ree, et al.
Published: (2024-12-01)

Efficacy and safety of sintilimab plus bevacizumab and CAPOX as first-line treatment for patients with RAS-mutant, microsatellite stable, metastatic colorectal cancer
by: Yanrong Wang, et al.
Published: (2025-03-01)

Refractory microsatellite stable metastatic colorectal cancer with ERBB2/ERBB3 mutation may be preferred population for regorafenib plus PD-1 inhibitor therapy: a real-world study
by: Xuan Dai, et al.
Published: (2023-08-01)

The next bastion to be conquered in immunotherapy: microsatellite stable colorectal cancer
by: Kai Ding, et al.
Published: (2023-12-01)

Sintilimab plus bevacizumab, oxaliplatin and capecitabine as first-line therapy in RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer: an open-label, single-arm, phase II trialResearch in context
by: Xuefeng Fang, et al.
Published: (2023-08-01)

Efficacy and Safety of Fruquintinib Combined with Sintilimab in Treatment of Advanced Microsatellite Stable Colorectal Cancer
by: LI Shan, et al.
Published: (2023-12-01)

Co-occurring mutations identify prognostic subgroups of microsatellite stable colorectal cancer
by: Luís Nunes, et al.
Published: (2024-11-01)

Epigenetic-related gene mutations serve as potential biomarkers for immune checkpoint inhibitors in microsatellite-stable colorectal cancer
by: Chao Liu, et al.
Published: (2022-11-01)

Progress of Biomarkers to Predict Response to Immune Checkpoint Inhibitors in Microsatellite Stability Colorectal Cancer
by: WANG Zhiqiang, et al.
Published: (2023-02-01)

Clinical, pathological, and adjuvant chemotherapy use differences among microsatellite unstable and microsatellite stable colon cancers
by: Baqir Hasan Jafry, et al.
Published: (2024-06-01)

Neoadjuvant immunotherapy for DNA mismatch repair proficient/microsatellite stable non-metastatic rectal cancer: a systematic review and meta-analysis
by: Huan Zhang, et al.
Published: (2025-01-01)

STR Profiling Reveals Tumor Genome Instability in Primary Mediastinal B-Cell Lymphoma
by: Natalya Risinskaya, et al.
Published: (2022-05-01)

Regorafenib with or without a programmed cell death protein 1 antibody as third‐line treatment for microsatellite stable metastatic colorectal cancer
by: Wen‐Zhuo He, et al.
Published: (2023-03-01)

Can neoadjuvant chemoradiotherapy combined with immunotherapy benefit patients with microsatellite stable locally advanced rectal cancer? a pooled and integration analysis
by: Yumin Yue, et al.
Published: (2023-10-01)

Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study
by: Elena Elez, et al.
Published: (2024-04-01)

Case report: Durable response from tegafur/gimeracil/oteracil (S-1) combined with fruquintinib and sintilimab as a third-line treatment for MSS metastatic colorectal cancer with a BRAF V600E mutation
by: Chunxia He, et al.
Published: (2024-12-01)

Microsatellite stable metastatic colorectal cancer without liver metastasis may be preferred population for regorafenib or fruquintinib plus sintilimab as third-line or above therapy:A real-world study
by: Caiyun Nie, et al.
Published: (2022-09-01)

Does PD-1 blockade play a decisive role in the pathological complete remission of unresectable MSS, BRAF V600E-mutated metastatic colorectal cancer: A case report
by: Li Tan, et al.
Published: (2023-01-01)

Fecal microbiota transplantation plus tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer: an open-label, single-arm, phase II trial (RENMIN-215)Research in context
by: Wensi Zhao, et al.
Published: (2023-12-01)

Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 studyResearch in context
by: Marwan Fakih, et al.
Published: (2023-04-01)

Immunotherapy regimens for metastatic colorectal carcinomas
by: Babar Bashir, et al.
Published: (2018-02-01)

Feasibility of stereotactic radiotherapy with pembrolizumab in patients with deficient mismatch repair/microsatellite unstable metastatic colorectal cancer
by: A. Gandini, et al.
Published: (2024-09-01)

Microsatellite instability-high status as a pan-cancer biomarker for immunotherapy efficacy
by: Thierry Landre, et al.
Published: (2025-02-01)

Complete remission in a pretreated, microsatellite-stable, KRAS-mutated colon cancer patient after treatment with sintilimab and bevacizumab and platinum-based chemotherapy: a case report and literature review
by: Lijuan He, et al.
Published: (2024-03-01)

Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
by: Pengfei Zhao, et al.
Published: (2019-05-01)

The Expression Patterns of Immune Checkpoint Molecules in Colorectal Cancer: An Analysis Based on Microsatellite Status
by: Sanghyun An, et al.
Published: (2024-03-01)

IDO1 inhibitor enhances the effectiveness of PD-1 blockade in microsatellite stable colorectal cancer by promoting macrophage pro-inflammatory phenotype polarization
by: Lv Guangzhao, et al.
Published: (2025-01-01)

Efficacy and safety of hepatic arterial infusion chemotherapy combined with fruquintinib and tislelizumab for patients with microsatellite stable colorectal cancer liver metastasis following failure of multiple-line therapy
by: Kanglian Zheng, et al.
Published: (2024-08-01)

CTLA-4 blockade in the treatment of colorectal cancer with microsatellite instability
by: Diana Russo, et al.
Published: (2021-03-01)

ASCL2 Affects the Efficacy of Immunotherapy in Colon Adenocarcinoma Based on Single-Cell RNA Sequencing Analysis
by: Lei Wu, et al.
Published: (2022-06-01)

Ongoing complete response after treatment cessation with dabrafenib, trametinib, and cetuximab as third-line treatment in a patient with advanced BRAFV600E mutated, microsatellite-stable colon cancer: A case report and literature review
by: Gudrun Piringer, et al.
Published: (2023-05-01)

Mismatch Repair Deficiency and Microsatellite Instability
by: Sandra Schöniger, et al.
Published: (2022-08-01)

Microsatellites grant more stable flanking genes
by: Joukhadar Reem, et al.
Published: (2012-10-01)

Meta-analysis of neoadjuvant immunotherapy for non-metastatic colorectal cancer
by: Long Zhou, et al.
Published: (2023-01-01)